Saturday 17 October 2026
Export SANA’s income statement to Excel — free account
Sana Biotechnology, Inc.
SANA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 43.6% and free cash flow fell 5.46%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.27
0.21
−8.47%
Follow SANA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(96.11%) | (118.70%) | (147.41%) | (152.87%) | |
| (47.13%) | (53.20%) | (59.09%) | (53.41%) | ||
ROIC |
(394.10%) | (854.59%) | (1,115.75%) | 0.00% | |
Return on Tangible Assets |
(150.09%) | (252.09%) | (473.57%) | (294.03%) | |
Free Cash Flow per Share |
(0.61) | (0.57) | (0.48) | (0.45) | |
Free Cash Flow |
(158.08) | (143.33) | (132.21) | (133.99) | |
Capital Expenditures |
0.27 | 0.49 | 0.34 | (1.75) | |
| Other line items | |||||
Cash ROIC |
(44.84%) | (47.23%) | (58.87%) | (41.97%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.68 | 0.59 | 0.55 | 0.62 | |
Depreciation/Fixed assets |
0.45 | 0.47 | 0.45 | 0.43 | |
Capex/Depreciation |
0.02 | 0.04 | 0.03 | (0.16) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.61) | (0.57) | (0.48) | (0.45) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates